Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
| ▸ | MTOR | P42345 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505912 | 0.92 | SLC6A3 (1.00) | SLC6A4SLC6A3SIGMAR1SMN1; SMN2CYP2D6 | |
| SCHEMBL726349 | 0.85 | SLC6A2 (1.00) | SLC6A4SLC6A3SIGMAR1SMN1; SMN2CYP2D6 | |
| SCHEMBL1239701 | 0.84 | SLC6A3 (0.83) | SLC6A3 | |
| Hydrochloric Acid SCHEMBL339982 | 0.84 | SMN1; SMN2 (1.00) | SLC6A4SLC6A3SIGMAR1SMN1; SMN2CYP2D6 | |
| SCHEMBL4199225 | 0.82 | SIGMAR1 (1.00) | SLC6A4SLC6A3SIGMAR1SMN1; SMN2CYP2D6 | |
| SCHEMBL83059 | 0.81 | SIGMAR1 (0.69) | SIGMAR1CYP2D6TP53CYP1A2TSHR | |
| SCHEMBL10259855 | 0.80 | SLC6A3 (0.65) | SLC6A3 | |
| SCHEMBL10000765 | 0.79 | SLC6A4 (0.97) | SLC6A4SLC6A3SIGMAR1SMN1; SMN2CYP2D6 | |
| SCHEMBL7449796 | 0.78 | SIGMAR1 (0.74) | SIGMAR1CYP2D6TP53CYP1A2TSHR | |
| SCHEMBL29386967 | 0.78 | KCNA3 (1.00) | SLC6A4SLC6A3SIGMAR1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211916-B2 | Central nervous system disorders; drug abuse; Parkinson's disease; antidepressants | WAYNE STATE UNIVERSITY (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2291378-A2 | N- AND O-SUBSTITUTED 4-Ý2-(DIPHENYLMETHOXY)-ETHYL¨-1-Ý(PHENYL)METHYL¨PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009094428-A2 | N- AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2008-07-31 | — | — | US | disclosed |
| US-6995268-B2 | N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | disclosed |
| WO-2001098266-A2 | N-AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | SLC6A3, SLC6A2, PNMT | SLC6A4 4/4885SLC6A3 1/4885SIGMAR1 86/4885 |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | SLC6A3, SLC6A2, PNMT | SLC6A4 4/4885SLC6A3 1/4885SIGMAR1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.